Moreover, because of the evolution of always more specific and potent P2X7 antagonists with a focus on CNS indications (Rech et al., 2016; Pevarello et al., 2017), we can optimistically expect that in the near future some new generation P2X7 drugs might be listed on the formulary and medication plan for ALS patients. Here, P2RX7 is linked to amyotrophic lateral sclerosis.